There are many exciting developments happening at Demetrix as we work to study, understand, and apply rare cannabinoids to improve the quality of life of people all around the world.
We’re also curating and sharing trustworthy insights on cannabinoids, their impact on health and wellness, and the evolving regulatory environment.
Lately, cannabigerol, also known as CBG, has been a big topic in the news. These articles highlight some of what we are starting to learn about this cannabinoid plus we included an article on a new regulatory development:
Could CBG be the next big thing?
The Cannabis Health Insider examines CBG, why it is significant, and how this extremely rare compound could open revenue streams for cannabis farmers.
CBG: A “Precious” Cannabinoid
Many personal care products currently contain CBD as it is believed that this cannabinoid has beneficial properties. While more research needs to be done into its efficacy, the beauty industry is also intrigued by the “precious” CBG cannabinoid and emerging research surrounding its capabilities. New Beauty took a closer look at CBG in this article.
DEA Evaluates 37 Applications to Grow Cannabis for research
Without access to cannabinoids, scientists cannot study them. To enable more scientific research of the many different parts of the plant, including cannabinoids, Science reports the DEA announced it will evaluate 37 applications to grow cannabis for medical research. This marks a significant regulatory development. At the same time, the agency will propose new rules for prospective growers, many of which are biotech firms, universities, and others in the research realm.